aytu20240610

0001437749-24-030075.txt : 20240926 0001437749-24-030075.hdr.sgml : 20240926 20240926163239 ACCESSION NUMBER: 0001437749-24-030075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240926 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 241329427 BUSINESS ADDRESS: STREET 1: 7900 E. UNION AVENUE STREET 2: SUITE 920 CITY: DENVER STATE: CO ZIP: 80237 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 7900 E. UNION AVENUE STREET 2: SUITE 920 CITY: DENVER STATE: CO ZIP: 80237 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 8-K 1 aytu20240610_8k.htm FORM 8-K aytu20240610_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 26, 2024

Date of Report (Date of earliest event reported):

AYTU BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38247		47-0883144
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7900 East Union Avenue, Suite 920

Denver, CO 80237

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (720) 437-6580

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		AYTU		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On September 26, 2024, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2024 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 26, 2024, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available live and for replay), and the press release includes instructions for accessing the webcast via the Company’s website or dialing in to the call. A replay of the call will be made available after the call on the Company’s website and via a telephone replay. Availability of the call replay posted on the Company’s website and via the telephone replay is at the Company’s discretion and may be discontinued at any time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit Description
99.1		Press Release dated September 26, 2024
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AYTU BIOPHARMA, INC.


Date: September 26, 2024	By:	/s/ Mark K. Oki
		Mark K. Oki
		Chief Financial Officer

EX-99.1 2 ex_686151.htm EXHIBIT 99.1 ex_686151.htm

Exhibit 99.1

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million

Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023

Full year fiscal 2024 adjusted EBITDA¹ improved to $9.2 million, up by $5.7 million compared to fiscal 2023

$20.0 million cash balance at June 30, 2024

Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levels

Company to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern time

DENVER, CO / September 26, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2024 full year and fourth quarter.

Full Year Fiscal 2024 Highlights

●

Consolidated net revenue was $81.0 million versus $107.4 million in the prior year period. The change primarily reflects the Company’s wind down of its Consumer Health Segment as part of the strategic mandate to focus its business solely on its Rx Segment, in an effort to drive long-term stockholder value.

●

ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 23% to $57.8 million versus $46.9 million in fiscal 2023. The Company expects net revenue growth across the Rx Segment in fiscal 2025.

●

Rx Segment gross margin improved to 75% in fiscal 2024 compared to 71% in fiscal 2023.

●

Consumer Health Segment net revenue during fiscal 2024 was $15.8 million, a decrease of 53% versus fiscal 2023, in line with the Company’s strategy to discontinue the Consumer Health Segment. As previously announced, the Company completed the wind down and divestiture its Consumer Health Segment in July 2024.

●

Net loss during fiscal 2024 was $15.8 million, or $2.86 net loss per share, compared to a net loss of $17.1 million, or $5.11 net loss per share, in fiscal 2023.

	●	Consolidated adjusted EBITDA was $9.2 million in fiscal 2024 compared to $3.5 million in fiscal 2023. The Company expects adjusted EBITDA growth in fiscal 2025.
	●	Cash and cash equivalents were $20.0 million at June 30, 2024, compared to $23.0 million at June 30, 2023.
	●	Successfully refinanced existing term loan and extended revolving credit facility on more favorable terms to the Company. In addition, the Company received $3.5 million of additional capital through the exercise of warrants, a portion of which was used to pay down the term loan indebtedness.

Q4 Fiscal 2024 Highlights

●

Consolidated net revenue was $18.0 million versus $30.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment and change in payor coverage, which impacted the Pediatric Portfolio. Pediatric Portfolio unit sales have grown 115% from July 1, 2024, to September 25, 2024.

●

ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue decreased 13% to $13.8 million versus $15.9 million in Q4 fiscal 2023, reflecting timing differences between the third and fourth quarters of the prior year’s period. Net revenue for the ADHD Portfolio increased 8% to $26.1 million in the second half of fiscal 2024 versus $24.1 million in the second half of fiscal 2023.

●

Rx Segment gross margin improved to 76% in Q4 2024 compared to 75% in Q4 2023.

●

Consumer Health Segment net revenue during Q4 2024 was $3.4 million, a decrease of 54% versus Q4 2023, in line with the Company’s strategy to discontinue the Consumer Health Segment. As previously announced, the Company completed the wind down and divestiture its Consumer Health Segment in July 2024.

●

Net loss during Q4 2024 was $4.6 million, or $0.82 net loss per share, compared to a net loss of $2.5 million, or $0.59 net loss per share, in Q4 2023.

●

Consolidated adjusted EBITDA was $1.5 million in Q4 2024 compared to $7.7 million in Q4 2023.

Management Discussion

“During fiscal 2024, we continued to successfully reposition Aytu as a growing specialty pharmaceutical company focused on commercializing novel prescription therapeutics. Over the past year, we successfully wound down and subsequently announced the sale of our Consumer Health business, which was completed in July 2024. This renewed focus on our higher-margin Rx Segment, coupled with the successful implementation of a number of cost saving initiatives, resulted in consolidated adjusted EBITDA of $9.2 million in fiscal 2024 compared to $3.5 million in fiscal 2023, an improvement of 162%” commented Josh Disbrow, Chief Executive Officer of Aytu. “Even more impressive is the transition from just two years ago when our consolidated adjusted EBITDA was a negative $21.5 million, highlighting a positive swing of more than $30 million over the past two years. Looking to the future, we continue to focus on driving prescription growth and leveraging the unique capabilities of our commercial platform, including Aytu RxConnect. This unique program provides tremendous benefits to patients and healthcare providers through transparent and predictable drug pricing, propelling future revenue growth and efficiencies.”

“Within our Rx Segment, our ADHD Portfolio net revenue increased 23% for the full year and experienced an 8% year-over-year increase during the second half of the fiscal year. Further, our Pediatric Portfolio continues to be impacted by payer changes that occurred in September 2023 but we remain convicted that the Pediatric Portfolio will return to growth from these current levels. We have implemented a number of commercial initiatives that give us confidence that we can get back to growth mode across the Pediatric Portfolio. We are seeing early momentum with those growth initiatives as pediatric product unit shipments have increased 115% from July 1, 2024, to September 25, 2024. We remain focused on driving prescription demand, improved coverage and patient access across our entire portfolio, and we fully expect to see Rx Segment net revenue and adjusted EBITDA growth from fiscal 2024 levels for the full year of fiscal 2025.”

“The strategic and operational initiatives we have implemented have allowed us to maintain a strong cash position, which was in excess of $20 million at the end of the fiscal year. This successful execution was further recognized financially through the receipt of $3.5 million of proceeds from the exercise of warrants, of which a portion was used as a capital source to pay down some of our existing term loan as we continue to strengthen our balance sheet. We also successfully refinanced our existing term loan and extended our revolving credit facility during the fourth quarter on more favorable terms to the Company. We remain confident that with our strategic focus on cash flows and earnings, we will continue to further enhance the financial profile of the Company via revenue growth and bottom-line improvement going forward.”

Non-Core Business Update

In June 2023, the Company announced that it had instituted a strategic mandate focusing its business solely on its Rx Segment, in an effort to drive long-term stockholder value. The Company has generated positive adjusted EBITDA for both fiscal 2024 and fiscal 2023, as well as for eight of the last reported nine quarters for Rx, excluding the Consumer Health Segment and pipeline R&D (the “Rx Business”). This concentration on the Rx Business follows the successful completion of the wind down and divestiture of the Consumer Health Segment in July of 2024.

This goal of emphasizing profitability was initially started with the indefinite suspension of all pipeline clinical development programs announced in October 2022 to minimize research and development expense until such time that the Company can fund those efforts with internally generated cash flows or through strategic partnerships. During fiscal 2023, the Consumer Health Segment contributed adjusted EBITDA of negative $3.6 million and pipeline programs contributed adjusted EBITDA of negative $2.6 million, while the Company’s Rx Business contributed adjusted EBITDA of $9.7 million. For fiscal 2024, the Company’s Rx Business contributed adjusted EBITDA of $10.8 million.

Segment Reporting

	Three Months Ended					Twelve Months Ended
	June 30,					June 30,
	2024			2023		2024		2023
	(in thousands)					(in thousands)
Rx Segment net revenue	$	14,593		$	23,313	$	65,183	$	73,799
Consumer Health Segment net revenue		3,383			7,419		15,819		33,600
Total net revenue	$	17,976		$	30,732	$	81,002	$	107,399

ADHD Portfolio net revenue	$	13,758		$	15,878	$	57,784	$	46,855
Pediatric Portfolio net revenue		841			7,225		7,280		25,377
Other ⁽¹⁾		(6	)		210		119		1,567
Total Rx Segment net revenue	$	14,593		$	23,313	$	65,183	$	73,799

⁽¹⁾ Other includes discontinued or deprioritized products.

Full Year Fiscal 2024 Financial Results

Net revenue for the full year fiscal 2024 was $81.0 million, compared to $107.4 million for the prior year period. The change primarily reflects the Company’s wind down of its Consumer Health Segment as part of the strategic mandate to focus its business solely on its Rx Segment, in an effort to drive long-term stockholder value.

Net revenue from the Rx Segment for the full year of fiscal 2024 was $65.2 million compared to $73.8 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) experienced a 23% increase in net revenue to $57.8 million for full year fiscal 2024, compared to the prior year period. The Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue decreased to $7.3 million largely due to payor changes that impacted prescriptions. Pediatric Portfolio unit shipments have increased 115% from July 1, 2024, through September 25, 2024.

Net revenue from the Consumer Health Segment was $15.8 million for full year fiscal 2024, a decrease of 53% over the same period last year. As previously announced, the Company completed the wind down and divestiture of its Consumer Health Segment in July of 2024 and expects that discontinuing this segment will improve operating cash flows and drive long-term stockholder value.

Consolidated gross profit was $54.6 million, or 67% of net revenue, for full year fiscal 2024, compared to $66.6 million, or 62% of net revenue, in the same period last year. Gross profit margin for the Rx Segment was 75% for full year fiscal 2024, compared with 71% in the prior year period.

Operating expenses, excluding amortization of intangible assets, restructuring costs, impairment expense and gain from contingent consideration, were $52.3 million for full year fiscal 2024 compared to $74.2 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.

Loss from operations for full year fiscal 2024 was $5.3 million compared to $17.1 million in the prior year period.

Net loss for full year fiscal 2024 was $15.8 million, or $2.86 net loss per share, compared to a $17.1 million net loss, or $5.11 net loss per share, in the prior year period. The fiscal 2024 full year results were impacted by $2.4 million of restructuring costs and $0.7 million of inventory impairment associated with the previously announced wind down of the Consumer Health Segment and Grand Prairie, Texas manufacturing facility as well as $4.4 million of derivative warrant liabilities loss due primarily to the increase in the Company’s stock price, $0.6 million loss on extinguishment of debt, and $1.8 million of income tax expense.

Consolidated adjusted EBITDA was $9.2 million for full year fiscal 2024, compared to $3.5 million in the prior year period, a $5.7 million increase. Adjusted EBITDA for the Rx Business was $10.8 million for full year fiscal 2024, compared to $9.7 million in the prior year period, a $1.2 million increase.

Cash and cash equivalents at June 30, 2024, were $20.0 million compared to $23.0 million at June 30, 2024.

Q4 Fiscal 2024 Financial Results

Net revenue for the fourth quarter of fiscal 2024 was $18.0 million, compared to $30.7 million for the prior year period.

Net revenue from the Rx Segment in the fourth quarter of fiscal 2024 was $14.6 million compared to $23.3 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) experienced a 13% decrease in net revenue to $13.8 million in the fourth quarter of fiscal 2024, compared to the prior year period, largely as a result of normalization of the ADHD market supply chain. Net revenue for the ADHD Portfolio increased 8% to $26.1 million in the second half of fiscal 2024 versus $24.1 million in the second half of fiscal 2023. This net revenue growth was achieved despite the ADHD market supply chain normalization that occurred in the second half of 2024. The Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue decreased to $0.8 million largely due to payor changes that impacted prescriptions. Growth of the ADHD Portfolio and Pediatric Portfolio is expected in fiscal 2025. Pediatric Portfolio unit shipments have increased 115% from July 1, 2024, through September 25, 2024.

Net revenue from the Consumer Health Segment was $3.4 million in the fourth quarter of fiscal 2024, a decrease of 54% over the same quarter last year. As previously announced, the Company completed the wind down and divestiture of its Consumer Health Segment in July of 2024 and expects that discontinuing this segment will improve operating cash flows and drive long-term stockholder value.

Consolidated gross profit was $11.9 million, or 66% of net revenue, in the fourth quarter of fiscal 2024, compared to $18.6 million, or 60% of net revenue, in the same quarter last year. Gross profit margin for the Rx Segment was 76% in the fourth quarter of fiscal 2024, compared with 75% in the prior year period.

Operating expenses, excluding amortization of intangible assets, restructuring costs, impairment expense and gain from contingent consideration, were $12.1 million in the fourth quarter of fiscal 2024 compared to $14.6 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.

Loss from operations during the fourth quarter of fiscal 2024 was $3.7 million compared to income from operations of $0.2 million in the prior year period.

Net loss during the fourth quarter of fiscal 2024 was $4.6 million, or $0.82 net loss per share, compared to a $2.5 million net loss, or $0.59 net loss per share, in the prior year period. The fiscal 2024 fourth quarter results were impacted by $2.1 million of restructuring costs and $0.7 million of inventory impairment associated with the previously announced wind down of the Consumer Health Segment and Grand Prairie, Texas manufacturing facility as well as $1.5 million of derivative warrant liabilities gain due primarily to the decrease in the Company’s stock price, $0.6 million loss on extinguishment of debt, and $0.7 million of income tax expense.

Consolidated adjusted EBITDA was $1.5 million in the fourth quarter of fiscal 2024, compared to $7.7 million in the prior year period, a $6.2 million decrease resulting largely from the decrease in the Pediatric Portfolio net revenue. Adjusted EBITDA for the Rx Business was $2.0 million in the fourth quarter of fiscal 2024, compared to $8.3 million in the prior year period, a $6.2 million decrease.

Conference Call Details

Date and Time: Thursday, September 26, 2024, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 216512.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51231, and accessible on the Investors section of the Company’s website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until October 10, 2024, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 51231.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company’s plans relating to the Company’s ability to efficiently wind down the Consumer Health Segment, the Company’s ability to complete the manufacturing transfer of Adzenys XR-ODT® and Cotempla XR-ODT®, the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or our business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of our products, our partners performing their required activities, our anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. We also refer you to (i) the risks described in “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10‑K and in the other reports and documents it files with the United States Securities and Exchange Commission.

Footnote 1

Aytu uses the term adjusted EBITDA, which is a term not defined under United States generally accepted accounting principles (“U.S. GAAP”). The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting adjusted EBITDA by certain categories allows investors to evaluate the various performance of these categories. The Company’s method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net income (loss) is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA. See below for a reconciliation of net income (loss) to adjusted EBITDA.

Contacts for Investors

Mark Oki, Chief Financial Officer

Aytu BioPharma, Inc.

moki@aytubio.com

Robert Blum or Roger Weiss

Lytham Partners

aytu@lythampartners.com

Aytu BioPharma, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended						Twelve Months Ended
	June 30,						June 30,
	2024			2023			2024			2023
Net revenue	$	17,976		$	30,732		$	81,002		$	107,399
Cost of sales		6,070			12,168			26,416			40,767
Gross profit		11,906			18,564			54,586			66,632

Operating expenses:
Selling and marketing		6,411			7,982			26,958			41,448
General and administrative		4,677			6,113			22,514			28,630
Research and development		1,044			465			2,791			4,095
Amortization of intangible assets		1,303			1,195			5,212			4,788
Restructuring costs		2,121			—			2,365			—
Impairment expense		—			3,105			—			5,705
Gain from contingent consideration		—			(465	)		—			(969	)
Total operating expenses		15,556			18,395			59,840			83,697
(Loss) income from operations		(3,650	)		169			(5,254	)		(17,065	)
Other income, net		48			82			568			184
Interest expense		(1,189	)		(1,334	)		(4,792	)		(4,963	)
Derivative warrant liabilities gain (loss)		1,463			(1,374	)		(4,004	)		4,793
Loss on extinguishment of debt		(594	)		—			(594	)		—
Loss before income tax		(3,922	)		(2,457	)		(14,076	)		(17,051	)
Income tax expense		(695	)		—			(1,768	)		—
Net loss	$	(4,617	)	$	(2,457	)	$	(15,844	)	$	(17,051	)

Basic and diluted weighted-average common shares outstanding		5,619,726			4,144,098			5,537,957			3,339,906
Basic and diluted net loss per share	$	(0.82	)	$	(0.59	)	$	(2.86	)	$	(5.11	)

Aytu BioPharma, Inc.

Consolidated Balance Sheets

(in thousands, except share data)

	June 30,
	2024			2023
ASSETS
Current assets:
Cash and cash equivalents	$	20,006		$	22,985
Accounts receivable, net		23,617			28,937
Inventories		12,633			11,995
Prepaid expenses and other current assets		5,635			7,162
Total current assets		61,891			71,079
Non-current assets:
Property and equipment, net		693			1,815
Operating lease right-of-use assets		829			2,054
Intangible assets, net		52,453			58,970
Other non-current assets		2,229			2,545
Total non-current assets		56,204			65,384
Total assets	$	118,095		$	136,463

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	10,440		$	13,478
Accrued liabilities		38,574			46,799
Revolving credit facility		2,395			1,563
Current portion of debt		1,857			85
Other current liabilities		8,962			7,090
Total current liabilities		62,228			69,015
Non-current liabilities:
Debt, net of current portion		10,877			14,713
Derivative warrant liabilities		12,745			6,403
Other non-current liabilities		4,529			6,975
Total non-current liabilities		28,151			28,091
Stockholders’ equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock, par value $.0001; 200,000,000 shares authorized; 5,972,638 and 5,517,174 shares issued and outstanding, respectively		1			1
Additional paid-in capital		347,688			343,485
Accumulated deficit		(319,973	)		(304,129	)
Total stockholders' equity		27,716			39,357
Total liabilities and stockholders’ equity	$	118,095		$	136,463

Aytu BioPharma, Inc.

Reconciliation of Net Loss to Adjusted EBITDA - Twelve Months Ended

(in thousands)

	Twelve Months Ended
	June 30, 2024
	Rx Business			Consumer Health			Pipeline R&D			Consolidated
Net loss - GAAP	$	(11,163	)	$	(3,698	)	$	(983	)	$	(15,844	)
Depreciation and amortization		5,910			1,547			—			7,457
Stock-based compensation expense		2,374			540			—			2,914
Other income, net		(568	)		—			—			(568	)
Interest expense		4,757			35			—			4,792
Derivative warrant liabilities loss		4,004			—			—			4,004
One-time transactions		1,001			—			—			1,001
Income tax expense		1,768			—			—			1,768
Inventory impairment due to wind down		—			730			—			730
Restructuring costs		2,156			209			—			2,365
Loss on extinguishment of debt		594			—			—			594
Adjusted EBITDA - non-GAAP	$	10,833		$	(637	)	$	(983	)	$	9,213

	Twelve Months Ended
	June 30, 2023
	Rx Business			Consumer Health			Pipeline R&D			Consolidated
Net loss - GAAP	$	(4,694	)	$	(9,761	)	$	(2,596	)	$	(17,051	)
Depreciation and amortization		6,271			1,116			—			7,387
Stock-based compensation expense		5,699			324			22			6,045
Other income, net		(184	)		—			—			(184	)
Interest expense		4,908			55			—			4,963
Gain from contingent consideration		(578	)		(391	)		—			(969	)
Derivative warrant liabilities gain		(4,793	)		—			—			(4,793	)
One-time transactions		300			—			—			300
Impairment expense		2,730			5,094			—			7,824
Adjusted EBITDA - non-GAAP	$	9,659		$	(3,563	)	$	(2,574	)	$	3,522

Aytu BioPharma, Inc.

Reconciliation of Net Income (Loss) to Adjusted EBITDA - Three Months Ended

(in thousands)

	Three Months Ended
	June 30, 2024
	Rx Business			Consumer Health			Pipeline R&D			Consolidated
Net loss - GAAP	$	(2,633	)	$	(1,385	)	$	(599	)	$	(4,617	)
Depreciation and amortization		1,398			385			—			1,783
Stock-based compensation expense		243			110			—			353
Other income, net		(48	)		—			—			(48	)
Interest expense		1,181			8			—			1,189
Derivative warrant liabilities gain		(1,463	)		—			—			(1,463	)
One-time transactions		150			—			—			150
Income tax expense		695			—			—			695
Inventory impairment due to wind down		—			730			—			730
Restructuring costs		1,912			209			—			2,121
Loss on extinguishment of debt		594			—			—			594
Adjusted EBITDA - non-GAAP	$	2,029		$	57		$	(599	)	$	1,487

	Three Months Ended
	June 30, 2023
	Rx Business			Consumer Health			Pipeline R&D			Consolidated
Net income (loss) - GAAP	$	3,677		$	(6,098	)	$	(36	)	$	(2,457	)
Depreciation and amortization		1,562			274			—			1,836
Stock-based compensation expense		784			115			—			899
Impairment expense		130			5,094			—			5,224
Other income, net		(82	)		—			—			(82	)
Interest expense		1,287			47			—			1,334
Gain from contingent consideration		(465	)		—			—			(465	)
Derivative warrant liabilities loss		1,374			—			—			1,374
Adjusted EBITDA - non-GAAP	$	8,267		$	(568	)	$	(36	)	$	7,663

EX-101.SCH 3 aytu-20240926.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 aytu-20240926_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 aytu-20240926_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 aytu-20240926_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo01.jpg begin 644 logo01.jpg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end GRAPHIC 8 logo.jpg begin 644 logo.jpg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ⅅ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end XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Sep. 26, 2024
Document Information [Line Items]
Entity, Registrant Name	AYTU BIOPHARMA, INC.
Document, Type	8-K
Document, Period End Date	Sep. 26, 2024
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-38247
Entity, Tax Identification Number	47-0883144
Entity, Address, Address Line One	7900 East Union Avenue
Entity, Address, Address Line Two	Suite 920
Entity, Address, City or Town	Denver
Entity, Address, State or Province	CO
Entity, Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	437-6580
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0001385818

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.aytu.com/20240926/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports aytu-20240926.xsd aytu-20240926_def.xml aytu-20240926_lab.xml aytu-20240926_pre.xml aytu20240610_8k.htm logo01.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aytu20240610_8k.htm": { "nsprefix": "aytu", "nsuri": "http://www.aytu.com/20240926", "dts": { "schema": { "local": [ "aytu-20240926.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "aytu-20240926_def.xml" ] }, "labelLink": { "local": [ "aytu-20240926_lab.xml" ] }, "presentationLink": { "local": [ "aytu-20240926_pre.xml" ] }, "inline": { "local": [ "aytu20240610_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.aytu.com/20240926/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240610_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240610_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aytu.com/20240926/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001437749-24-030075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-030075-xbrl.zip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�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

XML 19 aytu20240610_8k_htm.xml IDEA: XBRL DOCUMENT 0001385818 2024-09-26 2024-09-26 false 0001385818 8-K 2024-09-26 AYTU BIOPHARMA, INC. DE 001-38247 47-0883144 7900 East Union Avenue Suite 920 Denver CO 80237 720 437-6580 false false false false Common Stock AYTU NASDAQ false